CCHT(SZ:000661)2023-11-30 05:16Group 1: Company Strategy and Focus Areas - Jinsai Pharmaceutical aims to gradually transform into a company focused on children's health and women's health while maintaining stable performance in growth hormone products [1] - The company plans to diversify its product offerings and expand internationally [1] - In the children's health sector, the focus will be on areas such as childhood obesity, sexual development disorders, immunity, dermatology, respiratory, and mental health [2] Group 2: Product Development and Pipeline - Jinsai Pharmaceutical is building a product pipeline around existing products to ensure efficient operation across business units [2] - Key products in development include Lianping Reilin for central precocious puberty, long-acting follicle-stimulating hormone for assisted reproduction, and Jin Naxi monoclonal antibody for non-small cell lung cancer [2] - Several products are in various clinical trial phases, with promising data for Jin Naxi in gout treatment [3] Group 3: Research and Development Investment - The company emphasizes the importance of new product development and will strategically allocate R&D investments based on future development plans and short-term operational performance [3] Group 4: Market and Procurement Updates - Zhejiang Province has announced the proposed results for the fourth batch of centralized procurement of drugs and medical consumables, with final results pending [3]